Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 3/20 | 0.44 |
| ▸ | PDE3B | Q13370 | 16/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 16/20 | 0.39 |
| ▸ | PDE2A | O00408 | 12/20 | 0.39 |
| ▸ | P2RY12 | Q9H244 | 8/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31465468 | 0.74 | XDH (0.41) | PDE3BPDE3APDE2AP2RY12HPGD | |
| SCHEMBL10006703 | 0.70 | DUT (0.33) | DUT | |
| SCHEMBL20157445 | 0.69 | PDE3B (0.45) | PDE3BPDE3APDE2AP2RY12KDM4E | |
| SCHEMBL10006861 | 0.66 | PDE3B (0.47) | PDE3BPDE3APDE2AP2RY12KDM4E | |
| SCHEMBL12830376 | 0.66 | PDE3B (0.47) | PDE3BPDE3APDE2AP2RY12KDM4E | |
| SCHEMBL29349996 | 0.66 | PDE3B (0.47) | PDE3BPDE3APDE2AP2RY12KDM4E | |
| SCHEMBL10006459 | 0.65 | LMNA (0.36) | KDM4E | |
| SCHEMBL10007311 | 0.65 | DUT (0.30) | DUT | |
| SCHEMBL30358089 | 0.64 | PDE3B (0.49) | PDE3BPDE3APDE2AP2RY12KDM4E | |
| SCHEMBL21803342 | 0.64 | DUT (0.84) | DUTPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2476682-B1 | 8-OXODIHYDROPURINE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO LTD (JP) | 2017-04-26 | — | — | EP | disclosed |
| US-8735406-B2 | 8-oxodihydropurine derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2014-05-27 | — | — | US | disclosed |
| EP-2476682-A1 | 8-OXODIHYDROPURINE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2012-07-18 | — | — | EP | disclosed |
| US-20120172347-A1 | 8-OXODIHYDROPURINE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172347-A1 | 8-OXODIHYDROPURINE DERIVATIVE | FAAH, FAAH2, TPMT | DUT 147/4885PDE3B 1086/4885PDE3A 1005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.